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Purpose:  To  determine  whether  patients  with  isolated  primary  open-angle  glaucoma  (POAG)  have  evidence  of
chromosomal copy number alterations.
Methods: Twenty-seven Caucasian and African-American POAG patients and 12 ethnically matched controls were
carefully screened for possible glaucoma and tested for chromosomal copy number alterations using high resolution array
comparative genomic hybridization.
Results: No POAG patient had evidence of chromosomal copy number alterations when compared to normal ethnically
matched controls. Additionally, there was no evidence of somatic mosaicism in any tested POAG patient.
Conclusions: Chromosomal deletions and/or duplications were not detected in POAG patients as compared to controls.
Other chromosomal imbalances such as translocations, inversions, and some ploidies cannot be detected by current array
comparative genomic hybridization technology, and other nuclear genetic, mitochondrial abnormalities, or epigenetic
factors cannot be excluded as a possible contributing factor to POAG pathogenesis.
Glaucoma  is  one  of  the  leading  causes  of  blindness
worldwide [1] with a prevalence of over 2% in individuals
older  than  40  years  [2].  Primary  open-angle  glaucoma
(POAG) is the most common type of glaucoma in Western
countries and has risk factors that include elevated intraocular
pressure (IOP) and age [3], but these factors do not predict the
presence or degree of visual loss [4]. Up to half of all patients
with POAG have a positive family history, and the risk of
POAG is increased three to nine times in first-degree relatives
of  POAG  patients  [2,5].  These  observations  suggest  that
genetic factors contribute to POAG [1,6,7].
Currently, 14 chromosomal loci are linked to POAG by
the Human Genome Organization. Thus far, only three genes
associated with POAG have been identified within these loci
including myocilin [8], optineurin [9], and WD repeat domain
36 (WDR36) [10]. However, mutations in these three genes
are present in less than 5% of POAG patients [11]. Over 20
other gene variants have been associated with the disorder, but
in  general,  these  loci  have  been  identified  from  linkage
analysis of family data sets often without corroboration by
other investigators or in other populations. Therefore, the
cause of the genetic risk for the occurrence of POAG remains
largely unknown.
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Several chromosomal aberrations have been reported to
cause glaucoma, but in general, glaucoma has been associated
with an obvious genetic syndrome in these patients [12,13].
To our knowledge, no study has investigated chromosomal
copy  number  variations  in  patients  with  isolated  POAG.
Therefore, we examined possible chromosomal copy number
changes  in  POAG  patients  using  high  resolution  array
comparative genomic hybridization (array CGH) technology.
METHODS
Patients  and  controls:  Patients  were  selected  from  the
Glaucoma Clinic at Wills Eye Hospital (Philadelphia, PA)
after examination by a glaucoma specialist and after obtaining
informed consent approved by the Wills Institutional Review
Board. This research adhered to the tenets of the Declaration
of Helsinki, and all patients and controls signed an informed
consent  approved  by  the  Wills  Eye  Hospital  Institutional
Review Board.
Patients were eligible for inclusion in this study if they
met standard clinical criteria for POAG [14-16] including age
greater than 40 years, IOP greater than or equal to 21 mmHg
in at least one eye before treatment, normal-appearing anterior
chamber angles bilaterally on gonioscopy, and optic nerve
injury characteristic of POAG (with narrowed or absent rim,
asymmetric cupping of the optic discs, and static visual fields
compatible with optic disc appearance and with glaucoma).
Exclusion  criteria  included  historical,  neuroimaging,  or
biochemical evidence of another possible optic neuropathic
process affecting either eye, significant visual loss in both
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1594eyes  not  associated  with  glaucoma,  or  choosing  not  to
participate.
All  control  subjects  had  full  ophthalmologic
examinations and static perimetry. Each had IOPs below 21
mmHg  and  symmetry  in  the  two  eyes,  normal  anterior
Figure 1. Array CGH result for internal control. As an internal quality
control for the array CGH procedure, control DNA was hybridized
against POAG DNA of the opposite sex (ratio of +1 with regard to
chromosome X for XX POAG and XY control).
chambers, optic discs that were normal and symmetric in
appearance, entirely normal static perimetry (both eyes), and
no prior history of glaucoma. All patients and controls had
Humphrey Swedish interactive threshold algorithm (SITA)
achromatic static perimetry, stimulus III, 24–2 (Humphrey
Field Analyzer II; Carl Zeiss Meditec Inc., Dublin, CA).
Array CGH technique: Blood was collected in acid-citrate-
dextrose (ACD) tubes, and DNA was extracted using a Qiagen
Autopure LS instrument (Qiagen, Valencia, CA) following
the  manufacturer’s  recommended  procedure.  To  detect
chromosomal rearrangements, 2 μg of POAG patient genomic
DNA was competitively hybridized with 2 μg of ethnically
matched control DNA (as a reference sample) on an Agilent
Human Genome CGH 244A Oligo Microarray Kit (Agilent
Technologies Inc., Santa Clara, CA), which has an average
probe spacing across the human genome of 6.4 Kb. Briefly,
50 μl of DNA from POAG patients and controls was digested
using 50 units of Alu1 (Roche, Mannheim, Germany) and 50
units of Rsa1 (Roche) restriction enzymes in a 100 μl volume
with  10  μl  of  10X  Promega  Buffer  C.  Digestions  were
performed for 2 h at 37 °C. Digested samples were purified
using QIAprep Spin Miniprep columns (Qiagen) and eluted
according to the manufacturer's instructions. Samples were
then analyzed using the Agilent 2100 Bioanalyzer with the
DNA  7500  LabChip  Kit  and  DNA  7500  Software  Script
(Agilent) as per the manufacturer’s instructions. Alu1/Rsa1
digested  DNA  samples  were  labeled  using  the  BioPrime
Array  CGH  Labeling  Kit  (Invitrogen,  Carlsbad,  CA)
according to the manufacturer's protocol. POAG patient and
control DNA samples were systematically labeled with Alexa
Fluor 555 and 647, respectively.
Labeled products of each sample and control DNA were
purified using QIAprep Spin Miniprep columns (Qiagen),
mixed together, and checked on the Agilent 2100 Bioanalyzer
(Agilent) to evaluate the Alexa Fluor 555 integration into the
DNA samples. The following hybridization blocking reagents
were added to the purified Alexa Fluor 555 and 647 labeled
samples: 50 μg Cot-1 DNA (Invitrogen) and 50 μl of 10X
control targets (Agilent). The volume was brought to 250 μl
with double-distilled H2O, and 250 μl of 2X hybridization
buffer (Agilent) was added. The hybridization mixture was
then denatured at 100 °C for 3 min in a water bath. Samples
were immediately transferred to a 37 °C water bath for 30 min
to allow pre-annealing of the blocking agents to the labeled
sample. Samples were centrifuged for 5 min at 16,000x g and
immediately applied to the Agilent Human Genome CGH
244A  Oligo  Microarray  Kit  as  per  the  manufacturer's
recommendations. Hybridizations were performed at 65 °C
for 42 h.
Microarrays were disassembled in Agilent wash buffer-1
at room temperature (RT), transferred to a slide holder, and
incubated for 5 min with stirring in the Agilent wash buffer-1
at RT. The second washing step was performed for 1 min in
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were done with acetonitrile (Fisher Scientific, Fair Lawn, NJ)
and stabilization solutions (Agilent) for 1 min and 30 s at RT,
respectively. Microarray slides were immediately scanned in
the  Agilent  DNA  Microarray  Scanner  using  the  default
settings.
Data  analysis  was  performed  by  Agilent  Feature
Extraction  9.1  and  CGH  Analytics  3.4  (Agilent).  Log2
expression ratios were computed and normalized using CGH
Analytics 3.4 software. Putative chromosome copy number
changes were defined by intervals of three or more adjacent
probes with log2 ratios suggestive of a deletion or duplication
when compared with the log2 ratios of adjacent probes. The
quality-weighted interval score algorithm (ADM2) was used
to compute and assist in the identification of aberrations for a
given sample.
As  an  internal  quality  control  measure,  DNA  from
Caucasian patients were mixed with DNA from Caucasian
controls of the same and opposite sex and co-hybridized to the
244K chip (Figure 1). The same was done for POAG patients
and controls of African American ethnicity.
RESULTS
Clinical characteristics of the 27 POAG patients included in
this study are detailed in Table 1. Patient sex (15 males and
12  females)  and  ethnicity  (14  Caucasian  and  13  African-
American) were similar to that of the 12 controls, which were
carefully  screened  for  presence  of  POAG  or  other  optic
neuropathies  (5  males  and  7  females;  9  Caucasian  and  3
African-American).  The  mean  age  of  patients  (70.7±10.8
years) was somewhat greater than that of controls (61.1±10.8
years).
The  signal  ratio  of  each  patient  compared  to  a
simultaneously  tested  control  (patient-cy3/control-cy5)
documented  the  absence  of  chromosomal  copy  number
variations in any patient. No POAG patient had evidence of
somatic  mosaicism.  Representative  images  of  array  CGH
results are shown in Figure 2.
DISCUSSION
The 27 patients reported here met rigorous clinical criteria for
definite POAG [14-16] with elevated IOP, normal anterior
chamber, and evidence on the fundoscopic exam and visual
fields  of  glaucomatous  optic  nerve  damage.  By  clinical
criteria, they did not have evidence of other types of glaucoma
or  alternative  causes  of  optic  nerve  injury.  None  had
dysmorphism or an obvious genetic syndrome. They were
compared to 12 controls in which POAG and other evidence
of optic nerve damage were carefully excluded.
High  resolution  array  CGH  used  here  provides
quantitative information about the level of chromosome gain
or loss such as regions with a high level amplification or high
magnitude  deletion  and  will  recognize  a  chromosomal
duplication or deletion of a size greater than or equal to 6 Kb.
This technique did not detect any chromosomal copy number
variations of this size in POAG patients or controls. These
results  indicate  that  it  is  very  unlikely  that  chromosomal
deletions  or  duplications  are  universally  responsible  for
isolated POAG. Because of the relatively small sample size,
it remains possible that chromosomal aberrations might be
present in a portion of patients with isolated POAG. More
patients from multiple centers and various ethnicities would
need to be examined to make a general statement about the
absolute absence of chromosomal copy number variations in
the setting of POAG. No comment can be made about other
chromosomal imbalances such as translocations, inversions,
and some ploidies because these cannot be detected by current
array CGH technology.
These  negative  results  stand  in  contrast  to  reports  of
chromosomal  anomalies  causing  glaucoma  in  association
with a variety of genetic syndromes and abnormalities of
globe  development.  For  example,  several  chromosomal
anomalies have been reported to cause the Axenfeld-Rieger
syndrome (OMIM 602482) with variable ocular dysgenesis
associated with short height, stunted development of mid-
facial  features,  and  mental  deficiencies.  These  anomalies
include distal deletions of chromosome 6p [12], duplications
[17],  balanced  translocations  [18],  and  unbalanced
translocations [19], but they are all associated with abnormal
development  of  the  anterior  segment  and  early  onset
glaucoma  [20,21].  Similarly,  one  reported  patient  was
documented  to  have  partial  trisomy  of  7q  and  partial
Figure 2. Array CGH results for POAG patients versus controls.
Chromosomes shown were chosen randomly as representative of all
chromosomes and in all POAG patients tested. In the image, A
indicates Chromosome 1; B indicates Chromosome 13; C indicates
Chromosome 15; and D indicates Chromosome 18. When control
DNA was hybridized against POAG DNA, a signal ratio of zero (0)
was obtained, indicating the absence of chromosomal copy number
alterations.
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1596monosomy of 15q, and the Silver-Russell phenotype (OMIM
180860;  low  birth  weight,  delayed  maturation,  facial
dysmorphism,  clinodactyly,  ivory  epiphyses,  etc.)  with
congenital  glaucoma  [13]  while  another  had  a  balanced
translocation  t(9/17)(q34.1;q25)  and  the  Nail-Patella
Syndrome (OMIM 161200; dysplasia of the nails, absent or
hypoplastic patellae, and a low frequency of glaucoma and
ocular hypertension) [22]. Several reported patients with early
onset glaucoma and genetic syndromes lack a firm genetic
diagnosis  [23,24],  and  micro-anomalies  of  chromosomes
remain possible in some of these patients. The cohort reported
here had isolated POAG beginning in late adult life without
ocular malformations, dysmorphic features, or other evidence
of genetic syndromes, and to date, no such patient has been
reported to have an associated chromosome aberration.
In  summary,  we  used  high  resolution  array  CGH  to
evaluate a group of patients with isolated POAG and found
no  evidence  of  chromosomal  copy  number  variations.
Therefore, neither autosomal genetics [11] nor chromosomal
deletions/duplications  currently  provide  a  complete
explanation for the substantial familial association widely
recognized in POAG [2,5]. Although unrecognized genetic or
epigenetic factors remain possible, POAG patients do have a
variety  of  mitochondrial  [25]  and  metabolic  [26]
abnormalities that might put the optic nerve at risk. In this
regard,  POAG  may  have  certain  similarities  to  Leber
hereditary  optic  neuropathy,  another  spontaneous  optic
neuropathy with no obvious autosomal or chromosomal [27]
cause that also is associated with mitochondrial abnormalities
[28-30].
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